Skip to main content

Merck To Acquire Pandion Therapeutics For $60 Per Share In Cash

Merck and Pandion Therapeutics announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.